IP Library Granted Patent US 10,081,793
Granted Patent B2
US 10,081,793 · App. 14/775,987 · Granted Sep 25, 2018

Method for separating cells using immunorosettes and magnetic particles

Inventor: Andy Isamu Kokaji (Vancouver, CA)
Assignee: StemCell Technologies Inc.
C12N5/0634A23L2/52A61K31/07A61K31/122A61K31/197A61K31/198A61K31/221A61K31/355A61K31/375A61K31/385A61K31/4188A61K31/4415A61K31/455A61K31/51A61K31/519A61K31/525A61K31/593A61K31/714A61K33/00A61K33/04A61K33/06A61K33/30G01N1/40G01N33/54326G01N33/56966G01N33/56972A23L33/10A23L33/105A23L33/12A23L33/15A23L33/155A23L33/16A23L33/175
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,081,793
App. No.
14/775,987
Granted
Sep 25, 2018
Kind
B2
Abstract

The present invention relates to methods for separating target cells from non-target cells using immunorosettes and magnetic particles. The method involves contacting a sample containing target cells and secondary targets such as erythrocytes with an antibody composition which allows immunorosettes of the target cells and the secondary targets to form. The sample is subsequently contacted with a second antibody composition which allows the binding of magnetic particles to the formed immunorosettes and free secondary targets. The immunorosettes and secondary targets labeled with magnetic particles are separated from non-target cells using a magnetic field. The antibody composition optionally contains bifunctional antibodies or tetrameric antibody complexes.

Claims (18)

1. A selection method for separating target cells from non-target cells in a sample comprising target cells, erythrocytes and non-target cells, the method comprising:

a) contacting the sample with a first antibody composition comprising both (a) at least one antibody that binds to the target cells and (b) at least one antibody that binds to the erythrocytes, wherein the (a) at least one antibody that binds to the target cells is linked, either directly or indirectly, to (b) the at least one antibody that binds to the erythrocytes, under conditions to allow immunorosettes of the target cells and the erythrocytes to form;

b) contacting the sample with a second antibody composition comprising both (a) at least one antibody that binds to the erythrocytes either singly or within the immunorosettes and (b) at least one antibody that binds to magnetic particles, wherein the (a) at least one antibody that binds to the erythrocytes either singly or within the immunorosettes, is linked, either directly or indirectly, to (b) the at least one antibody that binds to the magnetic particles; wherein the contacting is performed in the presence of the magnetic particles under conditions to allow binding of the magnetic particles to the immunorosettes and/or the erythrocytes, and

c) separating the immunorosette—magnetic particle complexes and/or the erythrocyte—magnetic particle complexes from the sample using magnetic separation to separate the target cells from the non-target cells.

2. The method of claim 1 wherein the second antibody composition is bound to the magnetic particles prior to contacting with the sample.

3. The method of claim 1 wherein the second antibody composition is bound to the magnetic particles and added to the sample prior to contacting the sample with the first antibody composition.

4. The method of claim 1 , wherein the erythrocytes are already existing in or added to the sample.

5. The method of claim 1 , wherein the selection method is a positive selection method to select for desired cells and the target cells are the desired cells or a negative selection method to remove non-desired cells from the sample and the target cells are the non-desired cells.

6. The method of claim 1 , wherein the immunorosette-magnetic particle complexes and/or the erythrocyte-magnetic particle complexes are separated from the sample in step c) by placing the sample in a magnetic field gradient of sufficient strength to separate the immunorosette-magnetic particle complexes and/or the erythrocyte-magnetic particle complexes from the sample.

7. The method of claim 5 , wherein the method further comprises:

d) separating the target cells from the immunorosette—magnetic particle complexes.

8. The method of claim 1 , wherein the target cells are separated from the immunorosette—magnetic particle complexes by physical, chemical, enzymatic or thermal dissociation.

9. The method of claim 1 , wherein the method further comprises:

d) lysis of the erythrocytes in the immunorosettes and

e) separation of the target cells from the lysed erythrocytes and the magnetic particles.

10. The method of claim 1 , wherein the sample is blood, whole blood, bone marrow, fetal liver, cord blood, a buffy coat suspension, a leukapheresis sample, a pleural or peritoneal effusion or a sample of thymocytes and splenocytes.

11. The method of claim 1 , wherein the target cells are stem cells, progenitor cells, monocytes, lymphocytes, or granulocytes.

12. The method of claim 11 , wherein the lymphocytes are T cells, B cells or NK cells and the granulocytes are neutrophils, basophils or eosinophils.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2015
From: KOKAJI, ANDY ISAMU
To: STEMCELL TECHNOLOGIES INC.
Reel/Frame 036556/0665 →
Continuity (3)
Provisional Application 61788907 · Mar 15, 2013
Provisional Application 61929674 · Jan 21, 2014
Related Publication 20160187241A1 · Jun 30, 2016
Cited By (1)
US 12,449,433